Boston Scientific (BSX) stock: insider trades, news & valuation
Health Care · Strong buyingShare price and insider trades
Boston Scientific insider trading at a glance (Oct 9, 2026): in the past 12 months, 5 insiders bought $10.0M and 4 sold $24.3M of BSX stock on the open market, including a cluster buy that began Jul 31, 2026; P/E 17.3 vs. a sector median of 24.7.
Get emailed when insiders cluster-buy stocks like BSX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
BSX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $9.5M | 6 | — | 0 |
| Q2 2026 | $554K | 4 | — | 0 |
| Q1 2026 | — | 0 | $15.0M | 2 |
| Q4 2025 | — | 0 | $14.2M | 9 |
Valuation, profit and volume
Pick score 45/100Summary
Over the past 12 months, 5 Boston Scientific insiders reported open-market purchases totaling $10.0M, while 4 insiders reported sales totaling $24.3M. The most recent cluster buy began on Jul 31, 2026, when 3 insiders bought a combined $9.4M. 11 of 11 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
BSX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 29, 2026 | +3.2% | None | -0.1%S&P +0.1% | +1.8% |
| Apr 22, 2026 | -4.9% | None | +10.4%S&P +0.6% | -12.0% |
| Feb 4, 2026 | +4.0% | Sold $15.0M | -15.3%S&P -1.7% | -8.1% |
| Oct 22, 2025 | +3.3% | Sold $4.9M | +2.5%S&P +0.1% | -5.4% |
| Jul 23, 2025 | -0.6% | None | +3.0%S&P +0.9% | -0.0% |
| Apr 23, 2025 | +3.8% | None | +6.4%S&P +3.7% | +3.3% |
| Feb 5, 2025 | +4.9% | None | +1.4%S&P +0.8% | -5.6% |
| Oct 23, 2024 | +4.3% | None | -3.3%S&P -0.7% | +5.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
BSX news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
BSX short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded BSX
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | -38.2% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Jun 4, 2026 | Jul 13, 2026 | -12.5% |
| Markwayne MullinSenate | Bought $15,001 - $50,000 | Dec 29, 2025 | Jan 16, 2026 | -55.4% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Dec 17, 2025 | Jan 13, 2026 | -54.8% |
BSX stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- 8-K Executive or board change, Other material event
- News Elutia Receives $8 Million Payment from Boston Scientific ; Company Now Fully Funded into 2029 · manilatimes.net
- News Policy Lawmakers propose trip to worldwide medical technology center next year · wajr.com
- Positive Policy FDA Approves SpaceOAR Flex Hydrogel Rectal Spacer · renalandurologynews.com
- News Hoosier Hills Food Bank Community Book Fair : October 15 - 20 , 2026 · whcc105.com
- Negative AppLovin ( APP ) Falls to a Fresh 52 - Week Low at $290 . 43 · 247wallst.com
- News Elizabeth Martin - Garden City News · gcnews.com
- News Boston Scientific ( NYSE : BSX ) Stock Unloaded by Rep . Kevin Hern · tickerreport.com
- News Healthcare and Health IT News | Healthcare Dive · healthcaredive.com
- 8-K Executive or board change
- 8-K Cybersecurity incident
- 8-K Other material event
- 8-K Earnings release
- 8-K Restructuring costs
Insider transactions
Open-market purchases and sales. 114 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 26SEC | Susan E MoranoDirector | Buy | 2,04013,784 held (+17%) | $49.22 | $100K | -13.2% | — |
| Aug 7SEC | David C HabigerDirector | Buy | 2,10017,160 held (+14%) | $47.59 | $100K | -10.2% | — |
| Aug 5SEC | Michael F MahoneyCEO, President | Buy | 186,2401,590,024 held (+13%) | $48.33 | $9.0M | -11.6% | — |
| Aug 5SEC | David C HabigerDirector | Buy | 1,04214,920 held (+8%) | $48.07 | $50K | -11.1% | — |
| Aug 5SEC | David C HabigerDirector | Buy | 14015,060 held (+1%) | $48.59 | $7K | -12.1% | — |
| Aug 3SEC | Edward J LudwigDirector | Buy | 5,00030,359 held (+20%) | $45.48 | $227K | -6.0% | — |
| May 21SEC | Edward J LudwigDirector | Buy | 3,58025,359 held (+16%) | $56.68 | $203K | -24.6% | — |
| May 21SEC | David C HabigerDirector | Buy | 2,25013,878 held (+19%) | $55.92 | $126K | -23.6% | — |
| May 21SEC | David C HabigerDirector | Buy | 2,20011,628 held (+23%) | $56.95 | $125K | -25.0% | — |
| May 21SEC | Cheryl PegusDirector | Buy | 1,770new position | $56.49 | $100K | -24.4% | — |
| Feb 3SEC | Michael F MahoneyCEO, President | Sell Plan | 159,7011,411,735 held (−10%) | $93.49 | $14.9M | -54.3% | — |
| Feb 3SEC | Michael F MahoneyCEO, President | Sell Plan | 1,2001,571,436 held (−0%) | $94.06 | $113K | -54.6% | — |
| Dec 2SEC | Arthur C ButcherEvp& Grp Pres, Medsurg & Apac | Sell Plan | 17,31323,600 held (−42%) | $101.55 | $1.8M | -57.9% | — |
| Nov 6SEC | Ellen M ZaneDirector | Sell Plan | 12,89124,134 held (−35%) | $98.28 | $1.3M | -56.5% | — |
| Nov 4SEC | Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | Sell Plan | 29,472178,342 held (−14%) | $99.14 | $2.9M | -56.9% | — |
| Nov 4SEC | Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | Sell Plan | 16,928207,814 held (−8%) | $99.76 | $1.7M | -57.2% | — |
| Nov 4SEC | Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | Sell Plan | 3,600224,742 held (−2%) | $100.75 | $363K | -57.6% | — |
| Oct 28SEC | Ellen M ZaneDirector | Sell Plan | 9,99027,035 held (−27%) | $101.13 | $1.0M | -57.7% | — |
| Oct 28SEC | Ellen M ZaneDirector | Sell Plan | 2,90124,134 held (−11%) | $102.24 | $297K | -58.2% | — |
| Oct 1SEC | Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | Sell Plan | 41,755178,342 held (−19%) | $98.38 | $4.1M | -56.6% | — |
| Oct 1SEC | Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | Sell Plan | 8,245220,097 held (−4%) | $98.91 | $816K | -56.8% | — |
Insiders at Boston Scientific
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael F MahoneyCEO, President | $9.0M | $15.0M | Aug 5, 2026 | — |
| Joseph Michael FitzgeraldEvp & Group Pres, Cardiology | — | $9.9M | Aug 3, 2026 | — |
| Ellen M ZaneDirector | — | $2.6M | May 11, 2026 | — |
| Arthur C ButcherEvp& Grp Pres, Medsurg & Apac | — | $1.8M | May 4, 2026 | — |
| Edward J LudwigDirector | $430K | — | Aug 3, 2026 | — |
| David C HabigerDirector | $408K | — | Aug 7, 2026 | — |
| Susan E MoranoDirector | $100K | — | Aug 26, 2026 | — |
| Cheryl PegusDirector | $100K | — | May 21, 2026 | — |
| Padraig Andrew O'connorEvp, Global Operations | — | — | Sep 3, 2026 | — |
| Emily WoodworthSvp, Global Controller And Cao | — | — | Aug 12, 2026 | — |
| Jonathan MonsonCFO | — | — | Aug 11, 2026 | — |
| Jessica L MegaDirector | — | — | May 11, 2026 | — |
| Christophe Pierre WeberDirector | — | — | May 11, 2026 | — |
| David S WichmannDirector | — | — | May 11, 2026 | — |
| Vance R BrownEvp, Gc And Corp. Secretary | — | — | Feb 18, 2026 | — |
| Miriam O'sullivanSvp, Chief Hr Officer | — | — | Feb 18, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
BSX stock: common questions
Are Boston Scientific insiders buying BSX stock?
In the past 12 months, 5 insiders reported open-market purchases of BSX worth $10.0M. The latest was Director Susan E Morano bought $100K of BSX at $49.22 — first open-market purchase in our records.
Are Boston Scientific insiders selling BSX stock?
4 insiders reported sales worth $24.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BSX's P/E ratio?
BSX trades at about 17.3 times trailing earnings, compared with a median of 24.7 for the Health Care sector.
What is BSX's 52-week range?
Over the past year BSX has traded between $41.58 and $104.98. It last closed at $42.73 on Oct 9, 2026.